BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:HC022 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of HC022\, from ClinicalTrials.gov estimates
 .
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07306585-5422@assetmemo.bio
DTSTAMP:20261121T004046Z
DTSTART;VALUE=DATE:20270328
DTEND;VALUE=DATE:20270329
SUMMARY:HC022: Phase 1 readout est. (NCT07306585)
DESCRIPTION:HC022\, phase 1\, Systemic Lupus Erythematosus.\nStudy: The Saf
 ety\, Tolerability\, Pharmacokinetics\, Immunogenicity and Preliminary Eff
 icacy of HC022 Injection in Subjects With SLE/CLE\nEstimated primary compl
 etion: 28 March 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /hc022#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07306585
URL:https://assetmemo.bio/drug/hc022#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
